<DOC>
	<DOCNO>NCT00918879</DOCNO>
	<brief_summary>Saxagliptin new investigational medication develop treatment type 2 diabetes . This study design evaluate efficacy safety adult Indian patient inadequate glycaemic control diet exercise .</brief_summary>
	<brief_title>Evaluate Saxagliptin Adult Indian Patients With Type 2 Diabetes Inadequate Glycemic Control</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<criteria>Diagnosed Type 2 diabetes Patients drug naïve ie , receive medical treatment diabetes HbA1c ≥ 7.2 % ≤10.0 % ( enrolment ) , HbA1c ≥ 7.0 % ≤10.0 % ( randomization ) Insulin therapy within one year enrolment ( exception insulin therapy hospitalization use gestational diabetes ) Type 1 diabetes , history ketoacidosis hyperosmolar nonketonic koma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>DPP-4 inhibitor</keyword>
	<keyword>HbA1c</keyword>
	<keyword>Incretins</keyword>
</DOC>